word count: 247 14 Main text word count: 4313 15 16 17 Abstract 18 Congenital human cytomegalovirus (CMV) infections are the leading cause of newborn 19 hearing and central nervous system impairments worldwide. Currently, routine prenatal 20 screening for congenital CMV is not performed in the United States and confirmation in 21 suspected perinatal cases requires invasive sampling by amniocentesis. We hypothesized that
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38
Human cytomegalovirus (CMV) is the most common cause of congenital defects in the 39 United States and affects roughly 0.5-1.3% of live births worldwide (1, 2) , causing more 40 congenital disease than all disorders tested for in newborn screening combined (4). Congenital
41
CMV is associated with a variety of late-onset permanent disabilities such as hearing loss, 
49
Due to the significant risks posed by primary congenital CMV, prenatal CMV screening 50 via maternal serology has been proposed as an attractive approach to limit the incidence of 51 disease in this population (5). Yet, a variety issues can arise during interpretation of serology 52 results, making diagnosis challenging (6-9). Additionally, the utility of serologic screening is 53 limited to mothers with primary infections, thus excluding the substantial majority of congenital 54 CMV cases that are associated with maternal reactivation or reinfection. Consequently, the 55 current gold standard for diagnosing congenital CMV infection prenatally is amniocentesis, an 56 invasive procedure best performed after 21 weeks gestation. Because of the risks associated 57 with this procedure, amniocentesis is considered following radiologic and/or serologic evidence 58 for congenital disease (10-12). 
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We found that the median CMV fragment length in cfDNA was significantly shorter than 
231
By establishing the fragment size of CMV cfDNA through ultra-deep sequencing, we 232 have identified a potential mechanism contributing to the variation in CMV levels obtained from 233 different qPCR assays. Despite a recently implemented international standard, variation in 234 plasma CMV DNA levels measured by qPCR across different clinical laboratories has remained 235 high, with variation of up to 2 log 10 in copy number between assays (24). Amplicon size has 236 been identified as a major contributor to interassay variability, with larger amplicons having a 237 relatively lower IU/ml as compared to smaller amplicons (25). Given that amplicons in CMV 238 qPCR assays range in size from 52 to 340bp, it is reasonable to assume that PCR assays 239 developed for smaller amplicons would more readily amplify CMV cfDNA fragments. Previous 240 studies indicated that CMV DNA in plasma exists as highly fragmented, virion-free DNA,
241
suggesting that the cfDNA fragments measured here may constitute the vast majority of the 242 CMV DNA present in plasma (26, 27). Characterizing CMV cfDNA insert size may also assist in 243 designing target enrichment strategies and improving bioinformatic pipelines for infectious 244 disease screening. The CMV reads obtained from the cfDNA data were generally distributed 245 across the genome without preferential representation of any one region, although curiously low 246 coverage was seen across the RL12-RL13-UL1 gene region, which was also seen in a prior 247 cfDNA study (28) . Future studies will be needed to examine more samples to test the 248 generalizability of our single specimen estimation and to explore the effect of cfDNA in vivo as it 249 relates to CMV DNA quantitation.
250
To demonstrate that our approach has the robustness to identify other viral pathogens,
251
we interrogated the cfDNA sequencing data for evidence of iciHHV6. When our cohort of 
